Real-life Data of Constitutional Von Willebrand Disease in Western France
- Conditions
- Von Willebrand Diseases
- Registration Number
- NCT04887324
- Lead Sponsor
- Nantes University Hospital
- Brief Summary
The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center.
The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 922
- Constitutional Von Willebrand Disease patient, of any severity, with or without Von Willebrand Factors inhibitors
- Patient included in the research database BERHLINGO
- Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing agents available on the French market (at baseline)
- Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the 5 investigator centers
- Patients under guardianship
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Observational study, description of the global therapeutic modalities required for severe treated hemorrhagic events in constitutional Von Willebrand Disease patients of any severity 4 years Data collection for evaluation of Clotting factors quantities used by collection of treatments for severe hemorrhagic events
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
CHU Angers
🇫🇷Angers, France
CHR de Brest
🇫🇷Brest, France
CHU de Nantes
🇫🇷Nantes, France
CHU Rennes
🇫🇷Rennes, France
CH Le Mans
🇫🇷Le Mans, France